Indian Contract Development and Manufacturing Organisations (CDMOs) delivered robust Q2FY27 revenue expansion, standing out despite mixed earnings across the broader domestic pharmaceutical sector. Growth is largely propelled by global pharmaceutical giants accelerating outsourcing to de-risk supply chains and lower operational costs.

Domestic CDMOs are increasingly moving up the value chain, transitioning from generic active pharmaceutical ingredients (APIs) into complex custom synthesis, specialty intermediates, and peptides. Players like Blue Jet Healthcare are capitalizing on this structural tailwind across contrast media and chronic therapy segments, solidifying India's position as an indispensable high-margin global biopharma partner.